Exercise-induced hematuria exacerbated by improper hydration, low RBC MCV and dapagliflozin use

Abstract

Background: Dapagliflozin is a reversible, highly potent, and selective Sodium-Glucose Co-Transporter-2 inhibitor indicated for the treatment of type 2 diabetes. It is generally well tolerated, with a low risk of hypoglycaemia and diabetic ketoacidosis. Case presentation: We report a new adverse effect of dapagliflozin in a form of a transient hematuria, presenting in a 54-years-old male patient with type 2 diabetes after exercise and insufficient hydration. The process of hematuria in the patient is strongly linked with initial period of treatment. Conclusion: Dapagliflozin appears to have a rare adverse effect in the form of transient hematuria. Exercise, insufficient hydration, and low RBC MCV may play a role in such episodes.

Keywords

• Hematuria
• Dapagliflozin
• Adverse drug reaction
• SLGT2 inhibitor